115 related articles for article (PubMed ID: 8120556)
21. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.
Pro B; Hagemeister FB; McLaughlin P; Romaguera J; Rodriguez MA; Cabanillas F; Tiongson LP; Younes A
Leuk Lymphoma; 2006 Sep; 47(9):1818-21. PubMed ID: 17064994
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology Group.
Hochster HS; Oken MM; Winter JN; Gordon LI; Raphael BG; Bennett JM; Cassileth PA
J Clin Oncol; 2000 Mar; 18(5):987-94. PubMed ID: 10694548
[TBL] [Abstract][Full Text] [Related]
23. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.
Zinzani PL; Tani M; Fanti S; Stefoni V; Musuraca G; Vitolo U; Perrotti A; Fina M; Derenzini E; Baccarani M
Cancer; 2008 Feb; 112(4):856-62. PubMed ID: 18189293
[TBL] [Abstract][Full Text] [Related]
24. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Tsimberidou AM; McLaughlin P; Younes A; Rodriguez MA; Hagemeister FB; Sarris A; Romaguera J; Hess M; Smith TL; Yang Y; Ayala A; Preti A; Lee MS; Cabanillas F
Blood; 2002 Dec; 100(13):4351-7. PubMed ID: 12393618
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphoma.
Economopoulos T; Psyrri A; Fountzilas G; Tsatalas C; Anagnostopoulos A; Papageorgiou S; Xiros N; Dimopoulos MA
Leuk Lymphoma; 2008 Jan; 49(1):68-74. PubMed ID: 18203014
[TBL] [Abstract][Full Text] [Related]
26. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of lymphoma patients with fludarabine-based regimens: a report of 29 cases].
Huang HQ; Jiang WQ; Peng YL; Xia ZJ; Li YH; Li XB; Lin TY; Sun XF; Guan ZZ
Ai Zheng; 2004 Apr; 23(4):448-51. PubMed ID: 15087037
[TBL] [Abstract][Full Text] [Related]
28. Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi.
Vitolo U; Ladetto M; Boccomini C; Baldini L; De Angelis F; Tucci A; Botto B; Chiappella A; Chiarenza A; Pinto A; De Renzo A; Zaja F; Castellino C; Bari A; Alvarez De Celis I; Evangelista A; Parvis G; Gamba E; Lobetti-Bodoni C; Ciccone G; Rossi G
J Clin Oncol; 2013 Sep; 31(27):3351-9. PubMed ID: 23960180
[TBL] [Abstract][Full Text] [Related]
29. A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma.
Crawley CR; Foran JM; Gupta RK; Rohatiner AZ; Summers K; Matthews J; Micallef IN; Radford JA; Johnson SA; Johnson PW; Sweetenham JW; Lister TA
Ann Oncol; 2000 Jul; 11(7):861-5. PubMed ID: 10997815
[TBL] [Abstract][Full Text] [Related]
30. Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis.
Shin DY; Kim SJ; Yoon DH; Park Y; Kong JH; Kim JA; Kim BS; Kim HJ; Won JH; Park SK; Kim WS
Cancer Chemother Pharmacol; 2016 Apr; 77(4):865-73. PubMed ID: 26984211
[TBL] [Abstract][Full Text] [Related]
31. The role of mitoxantrone in the treatment of indolent lymphomas.
Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL
Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217
[TBL] [Abstract][Full Text] [Related]
32. FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma.
Zinzani PL; Bendandi M; Tura S
Eur J Haematol; 1995 Oct; 55(4):262-6. PubMed ID: 7589345
[TBL] [Abstract][Full Text] [Related]
33. Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study.
Bordonaro R; Petralia G; Restuccia N; Todaro AM; Serraino D; Giuffrida D; Cordio S; Giannitto-Giorgio C; Salice P; Ursino M; Novello G; Marletta F; Manusia M
Leuk Lymphoma; 2004 Jan; 45(1):93-100. PubMed ID: 15061203
[TBL] [Abstract][Full Text] [Related]
34. Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients.
Ma SY; Au WY; Chim CS; Lie AK; Lam CC; Tse E; Leung AY; Liang R; Kwong YL
Br J Haematol; 2004 Mar; 124(6):754-61. PubMed ID: 15009063
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma.
Abbasi MR; Sparano JA; Sarta C; Wiernik PH
Med Oncol; 2003; 20(1):53-8. PubMed ID: 12665685
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527
[TBL] [Abstract][Full Text] [Related]
37. Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
Zinzani PL; Pellegrini C; Broccoli A; Gandolfi L; Stefoni V; Casadei B; Maglie R; Argnani L; Pileri S
Hematol Oncol; 2015 Sep; 33(3):141-6. PubMed ID: 24986783
[TBL] [Abstract][Full Text] [Related]
38. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
Sacchi S; Pozzi S; Marcheselli R; Federico M; Tucci A; Merli F; Orsucci L; Liberati M; Vallisa D; Brugiatelli M;
Cancer; 2007 Jul; 110(1):121-8. PubMed ID: 17503433
[TBL] [Abstract][Full Text] [Related]
39. Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group.
Santini G; Chisesi T; Nati S; Porcellini A; Zoli V; Rizzoli V; Zupo S; Marino G; Rubagotti A; Polacco A; Spriano M; Vimercati R; Congiu AM; Ravetti JL; Aversa S; Candela M; Patti C
Leuk Lymphoma; 2004 Jun; 45(6):1141-7. PubMed ID: 15359993
[TBL] [Abstract][Full Text] [Related]
40. Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.
Sarris AH; Jiang Y; Tsimberidou AM; Thomaides A; Rassidakis GZ; Ford RJ; Medeiros LJ; Cabanillas F; McLaughlin P
Semin Oncol; 2002 Feb; 29(1 Suppl 2):48-55. PubMed ID: 11842389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]